Compounded tirzepatide

Fifty 410

Fifty 410 costs $199 a month for compounded tirzepatide. It advertises $99. That is the starting dose, and it rises as your dose does.

A real month costs$199advertised $99 +$100.00 gap
EvidenceReported
Billing cyclemonthly
Price across dosesClimbs with the dose
Where it shipsNot stated
FDA warning letterOne on filestill listed here

Visit Fifty 410

The arithmeticOne month = 30.4375 days

  1. Fifty 410 advertises

    Read on Fifty 410's own site

    $99.00

  2. The card is charged $199.00, not $99.00

    The advertised figure is not the amount that leaves the account.

    + $100.00

  3. And it is charged once a calendar month

    + $0.00

A real month$199.00

A real month costs $100.00 more than the figure advertised.

The price above is the starting dose, and it rises as your dose does. This seller does not publish how far, so treat it as an entry price rather than what you will be paying in six months.

Where it sits, and what costs less

$54median $199$325+

186 cheaper · 49%177 dearer · 46%

The most expensive 9 sellers charge between $325 and $500 a month.

  1. Fidelity Medical Clinicstarting dose$54
  2. Collective$76
  3. Embody$79
  4. NuuVim$79
  5. NextMeds$79
  6. Fifty 410$199

Another 181 sellers are cheaper than Fifty 410. The whole cheapest list →

What else this seller sells

The same seller appears in our data for one other medication.

  • tirzepatide$133 a month

Worked out the same way as the semaglutide price above, and kept separate from it.

FDA has written to this seller

On FDA issued warning letter 721481 to Aspen Aesthetics dba Fifty 410 of Prosper , TX 75078. Its stated subject:

False & Misleading Claims/Misbranded (Telehealth)

Read the letter on fda.gov · The letter names fifty410.com — the same site this page links to.

This seller stays in the index, at its real price. A warning letter is something you should see and weigh for yourself — an index that quietly dropped the worst records would be least useful exactly when it matters most. How we screen for these →